1. Epigenetics
    Stem Cell/Wnt
    JAK/STAT Signaling
  2. JAK

Ruxolitinib phosphate (Synonyms: INCB018424 phosphate; INCB 018424 phosphate; INCB-018424 phosphate; Ruxolitinib)

Cat. No.: HY-50858 Purity: 99.89%
Data Sheet SDS Handling Instructions

Ruxolitinib (phosphate) is the first potent JAK1/2 inhibitor with IC50 values of 3.3 nM/2.8 nM, more than 130-fold selectivity for JAK1/2 versus JAK3.

For research use only. We do not sell to patients.
Ruxolitinib phosphate Chemical Structure

Ruxolitinib phosphate Chemical Structure

CAS No. : 1092939-17-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
5 mg USD 60 In-stock
10 mg USD 72 In-stock
50 mg USD 132 In-stock
100 mg USD 180 In-stock
200 mg USD 288 In-stock
500 mg USD 528 In-stock
1 g USD 768 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Ruxolitinib phosphate:

    Ruxolitinib phosphate purchased from MCE. Usage Cited in: J Biol Chem. 2015 Nov 27;290(48):29022-34.

    106 autonomous Ba/F3 cells stably transduced with ALL-associated JAK3 mutant V674A or double mutant L857P/Y100A are treated with increasing concentration of Ruxolitinib (0–2 μM). Two hours after treatment, the cells are lysed and subjected to Western blot analysis. Phosphorylation of STAT5, JAK3, and JAK1 is detected using specific anti-pY694 STAT5, anti-pY980/81 JAK3, and anti-pY1034/35 JAK1 antibodies. Membranes are reprobed with anti-STAT5, anti-JAK3, anti-JAK1, and anti-β-actin an

    Ruxolitinib phosphate purchased from MCE. Usage Cited in: Blood. 2013 Nov 21;122(22):3628-31.

    Ruxolitinib decreases spleen weight. Mice are sacrificed on day 21 or 24 to evaluate spleen size.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    Ruxolitinib (phosphate) is the first potent JAK1/2 inhibitor with IC50 values of 3.3 nM/2.8 nM, more than 130-fold selectivity for JAK1/2 versus JAK3.

    IC50 & Target

    IC50: 3.3 nM (JAK1), 2.8 nM (JAK2)

    In Vitro

    Ruxolitinib (INCB018424) potently and selectively inhibits JAK2V617F-mediated signaling and proliferation. Ruxolitinib inhibits the growth of HEL cells with EC50 of 186 nM. Ruxolitinib markedly increases apoptosis in Ba/F3-EpoR-JAK2V617F cell system, and inhibits hematopoietic progenitor cell proliferation in primary MPN patient samples[1].

    In Vivo

    Ruxolitinib (180 mg/kg, p.o.) reduces the tumor burden of mice inoculated with JAK2V617F-expressing cells without causing anemia or lymphopenia[1].

    Clinical Trial
    View MoreCollapse
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.4730 mL 12.3652 mL 24.7304 mL
    5 mM 0.4946 mL 2.4730 mL 4.9461 mL
    10 mM 0.2473 mL 1.2365 mL 2.4730 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay

    Ruxolitinib phosphate is dissolved in 0.2% DMSO.

    Cells are seeded at 2000/well of white bottom 96-well plates, treated with compounds from DMSO stocks (0.2% final DMSO concentration), and incubated for 48 hours at 37°C with 5% CO2. Viability is measured by cellular ATP determination using the Cell-Titer Glo luciferase reagent or viable cell counting. Values are transformed to percent inhibition relative to vehicle control, and IC50 curves are fitted according to nonlinear regression analysis of the data using PRISM GraphPad. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    Ruxolitinib phosphate is dissolved in vehicle (5% dimethyl acetamide, 0.5% methocellulose).

    Mice are fed standard rodent chow and provided with water ad libitum. Ba/F3-JAK2V617F cells (105 per mouse) are inoculated intravenously into 6- to 8-week-old female BALB/c mice. Survival is monitored daily, and moribund mice are humanely killed and considered deceased at time of death. Treatment with vehicle (5% dimethyl acetamide, 0.5% methocellulose) or Ruxolitinib (INCB018424) begins within 24 hours of cell inoculation, twice daily by oral gavage. Hematologic parameters are measured using a Bayer Advia120 analyzed, and statistical significance is determined using Dunnett testing. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.


    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 31 mg/mL; H2O: 5.4 mg/mL (Need ultrasonic or warming)

    Ruxolitinib phosphate is dissolved in 5% dimethyl acetamide, 0.5% methylcellulose[2].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.


    Purity: 99.89%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ruxolitinib phosphate
    Cat. No.: